Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model

Gynecologic Oncology

Volumn 133, Issue 3, 2014, Pages 607-615

  Groeneweg, Jolijn W ^a,b   Hall, Tracilyn R ^a,b   Zhang, Ling ^a   Kim, Minji ^a   Byron, Virginia F ^a   Tambouret, Rosemary ^a,b   Sathayanrayanan, Sriram ^c   Foster, Rosemary ^a,b   Rueda, Bo R ^a,b   Growdon, Whitfield B ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Gamma secretase inhibitor; Notch; Patient derived xenograft model; Uterine serous carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; MESSENGER RNA; MRK 003; NOTCH1 RECEPTOR; PACLITAXEL; TRANSCRIPTION FACTOR HES 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOMA CELL LINE; CELL COUNT; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DOSE RESPONSE; DOWN REGULATION; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IN VITRO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; TUMOR GROWTH; TUMOR XENOGRAFT; UTERINE SEROUS CARCINOMA; UTERUS CARCINOMA;

GAMMA SECRETASE INHIBITOR; NOTCH; PATIENT DERIVED XENOGRAFT MODEL; UTERINE SEROUS CARCINOMA;

ADENOCARCINOMA; AGED; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CYCLIC S-OXIDES; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MICE; RECEPTOR, NOTCH1; RNA, MESSENGER; SIGNAL TRANSDUCTION; THIADIAZOLES; TUMOR CELLS, CULTURED; UTERINE NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84901666327     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.03.560     Document Type: Article

References (40)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. J.V. Bokhman Two pathogenetic types of endometrial carcinoma Gynecol Oncol 15 1983 10 17
3. F. Amant, P. Moerman, P. Neven, D. Timmerman, E. Van Limbergen, and I. Vergote Endometrial cancer Lancet 366 2005 491 505
4. C.A. Hamilton, M.K. Cheung, K. Osann, L. Chen, N.N. Teng, and T.A. Longacre et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers Br J Cancer 94 2006 642 646
5. D.M. Boruta II, P.A. Gehrig, A.N. Fader, and A.B. Olawaiye Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review Gynecol Oncol 115 2009 142 153
6. M.G. del Carmen, M. Birrer, and J.O. Schorge Uterine papillary serous cancer: a review of the literature Gynecol Oncol 127 2012 651 661
7. S. Artavanis-Tsakonas, M.D. Rand, and R.J. Lake Notch signaling: cell fate control and signal integration in development Science 284 1999 770 776
8. S.J. Bray Notch signalling: a simple pathway becomes complex Nat Rev Mol Cell Biol 7 2006 678 689
9. R. Kopan, and M.X. Ilagan The canonical Notch signaling pathway: unfolding the activation mechanism Cell 137 2009 216 233
10. S.M. McAuliffe, S.L. Morgan, G.A. Wyant, L.T. Tran, K.W. Muto, and Y.S. Chen et al. Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy Proc Natl Acad Sci U S A 109 2012 E2939 E2948
11. J.L. Avila, and J.L. Kissil Notch signaling in pancreatic cancer: oncogene or tumor suppressor? Trends Mol Med 19 2013 320 327
12. J.T. Park, M. Li, K. Nakayama, T.L. Mao, B. Davidson, and Z. Zhang et al. Notch3 gene amplification in ovarian cancer Cancer Res 66 2006 6312 6318
13. X. Chen, M.M. Thiaville, L. Chen, A. Stoeck, J. Xuan, and M. Gao et al. Defining NOTCH3 target genes in ovarian cancer Cancer Res 72 2012 2294 2303
14. Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
15. M. Mori, T. Miyamoto, S. Ohno, Y. Miyake, T. Sakaguchi, and E. Ohno Diagnostic utility of notch-1 immunocytochemistry in endometrial cytology Acta Cytol 56 2012 166 170
16. Y. Mitsuhashi, A. Horiuchi, T. Miyamoto, H. Kashima, A. Suzuki, and T. Shiozawa Prognostic significance of Notch signalling molecules and their involvement in the invasiveness of endometrial carcinoma cells Histopathology 60 2012 826 837
17. L. Cobellis, F. Caprio, E. Trabucco, A. Mastrogiacomo, G. Coppola, and L. Manente et al. The pattern of expression of Notch protein members in normal and pathological endometrium J Anat 213 2008 464 472
18. V. Jonusiene, A. Sasnauskiene, N. Lachej, D. Kanopiene, D. Dabkeviciene, and S. Sasnauskiene et al. Down-regulated expression of Notch signaling molecules in human endometrial cancer Med Oncol 30 2013 438
19. N. Takebe, D. Nguyen, and S.X. Yang Targeting Notch signaling pathway in cancer: clinical development advances challenges Pharmacol Ther 141 2014 140 149
20. P. Rizzo, C. Osipo, K. Foreman, T. Golde, B. Osborne, and L. Miele Rational targeting of Notch signaling in cancer Oncogene 27 2008 5124 5131
21. A.F. Schott, M.D. Landis, G. Dontu, K.A. Griffith, R.M. Layman, and I. Krop et al. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors Clin Cancer Res 19 2013 1512 1524
22. M. Mori, T. Miyamoto, H. Yakushiji, S. Ohno, Y. Miyake, and T. Sakaguchi et al. Effects of N-[N-(3, 5-difluorophenacetyl-L-alanyl)]-S-phenylglycine t-butyl ester (DAPT) on cell proliferation and apoptosis in Ishikawa endometrial cancer cells Hum Cell 25 2012 9 15
23. H.D. Lewis, M. Leveridge, P.R. Strack, C.D. Haldon, J. O'Neil, and H. Kim et al. Apoptosis in T cell acute lymphoblastic leukemia cells after cell cycle arrest induced by pharmacological inhibition of notch signaling Chem Biol 14 2007 209 219
24. M. Mizuma, Z.A. Rasheed, S. Yabuuchi, N. Omura, N.R. Campbell, and R.F. de Wilde et al. The gamma secretase inhibitor MRK-003 attenuates pancreatic cancer growth in preclinical models Mol Cancer Ther 11 2012 1999 2009
25. V. Ramakrishnan, S. Ansell, J. Haug, D. Grote, T. Kimlinger, and M. Stenson et al. MRK003, a gamma-secretase inhibitor exhibits promising in vitro pre-clinical activity in multiple myeloma and non-Hodgkin's lymphoma Leukemia 26 2012 340 348
26. J. Morgan, A.V. Hoekstra, E. Chapman-Davis, J.L. Hardt, J.J. Kim, and B.M. Buttin Synuclein-gamma (SNCG) may be a novel prognostic biomarker in uterine papillary serous carcinoma Gynecol Oncol 114 2009 293 298
27. D.P. English, D.M. Roque, L. Carrara, S. Lopez, S. Bellone, and E. Cocco et al. HER2/neu gene amplification determines the sensitivity of uterine serous carcinoma cell lines to AZD8055, a novel dual mTORC1/2 inhibitor Gynecol Oncol 131 2013 753 758
28. M.D. Curley, V.A. Therrien, C.L. Cummings, P.A. Sergent, C.R. Koulouris, and A.M. Friel et al. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer Stem Cells 27 2009 2875 2883
29. M.W. Pfaffl A new mathematical model for relative quantification in real-time RT-PCR Nucleic Acids Res 29 2001 e45
30. M. Wang, J. Wang, L. Wang, L. Wu, and X. Xin Notch1 expression correlates with tumor differentiation status in ovarian carcinoma Med Oncol 27 2010 1329 1335
31. D.K. Armstrong, B. Bundy, L. Wenzel, H.Q. Huang, R. Baergen, and S. Lele et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer N Engl J Med 354 2006 34 43
32. J. Konishi, K.S. Kawaguchi, H. Vo, N. Haruki, A. Gonzalez, and D.P. Carbone et al. Gamma-secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers Cancer Res 67 2007 8051 8057
33. M. Fouladi, C.F. Stewart, J. Olson, L.M. Wagner, A. Onar-Thomas, and M. Kocak et al. Phase I trial of MK-0752 in children with refractory CNS malignancies: a pediatric brain tumor consortium study J Clin Oncol 29 2011 3529 3534
34. I. Krop, T. Demuth, T. Guthrie, P.Y. Wen, W.P. Mason, and P. Chinnaiyan et al. Phase I pharmacologic and pharmacodynamic study of the gamma secretase (Notch) inhibitor MK-0752 in adult patients with advanced solid tumors J Clin Oncol 30 2012 2307 2313
35. A. Pannuti, K. Foreman, P. Rizzo, C. Osipo, T. Golde, and B. Osborne et al. Targeting Notch to target cancer stem cells Clin Cancer Res 16 2010 3141 3152
36. B.M. Slomovitz, R.R. Broaddus, T.W. Burke, N. Sneige, P.T. Soliman, and W. Wu et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma J Clin Oncol 22 2004 3126 3132
37. A.D. Santin, S. Bellone, S. Van Stedum, W. Bushen, L.E. De Las Casas, and S. Korourian et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization Gynecol Oncol 98 2005 24 30
38. F.E. Odicino, E. Bignotti, E. Rossi, B. Pasinetti, R.A. Tassi, and C. Donzelli et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization Int J Gynecol Cancer 18 2008 14 21
39. K. Pandya, K. Meeke, A.G. Clementz, A. Rogowski, J. Roberts, and L. Miele et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence Br J Cancer 105 2011 796 806
40. C. Osipo, P. Patel, P. Rizzo, A.G. Clementz, L. Hao, and T.E. Golde et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor Oncogene 27 2008 5019 5032